Table 1 Overview of country and regional guidance for RZV vaccination, highlighting specific recommendations for adults with asthma and COPD
From: Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
Regulator (country) | RZV vaccination recommendations | Refs. |
|---|---|---|
CDC–ACIP (US) | General population Aged ≥ 50 years (including special populations e.g., chronic renal failure, diabetes mellitus, rheumatoid arthritis, and chronic pulmonary disease) Immunocompromised adults Aged ≥ 19 years for adults who are or will be immunodeficient or immunosuppressed because of disease or therapy | |
CIQ (Canada –Quebec) | General population Aged ≥ 50 years and more particularly aged ≥ 65 years Special population • Aged ≥ 50 years with chronic diseases who are at high risk of shingles should be prioritized for vaccination • Aged ≥ 18 years for immunosuppressed adults and can be considered for adults with chronic diseases who are at high risk of shingles, without necessarily being immunocompromised or immunosuppressed (e.g., RA, SLE, chronic inflammatory bowel disease, COPD or bronchial asthma, chronic kidney disease and diabetes) | [77] |
STIKO (Germany) | General population Aged ≥ 60 years Special populations Aged ≥ 50 years with increased health risk due to an underlying disease (e.g., congenital or acquired immunodeficiency or immunosuppression, HIV infection, RA, SLE, inflammatory bowel disease, COPD or bronchial asthma, chronic renal failure, or diabetes mellitus) | [73] |
Ministero della Salut (Italy) | General population Aged ≥ 65 years, actively offered Special populations Aged ≥ 50 years, actively offered to those with diabetes mellitus, cardiovascular pathology, COPD, and subjects intended for immunosuppressive therapy | [74] |
OFSP (Switzerland) | General population Aged ≥ 65 years who are immunocompetent Special populations • Aged ≥ 18 years with a current severe immunodeficiency or will receive an immunosuppressive treatment in the foreseeable future • Aged ≥ 50 years with a current or future (cellular) immunodeficiency associated with an increased risk for HZ (e.g., undergoing active cancer treatment; HIV; end-stage renal disease or on dialysis; receiving biologics, AZA, MTX or maintenance low-dose corticosteroid treatment; or with other underlying conditions affecting immunity including RA, severe asthma/COPD, inadequately controlled diabetes mellitus type 1 and other autoimmune diseases) | [75] |